François Goehringer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
François Goehringer has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
C. Rabaud
CHRU de Nancy, Nancy, France
2 shared publicationsT. May
CHRU de Nancy, Nancy, France
2 shared publicationsAnne Lavergne
Laboratoire des Interactions Virus Hôte, Institut Pasteur de la Guyane, Cayenne, France
1 shared publicationB. Demore
CHRU de Nancy, Nancy, France
1 shared publication- Benito Almirante
Infectious Diseases Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain
1 shared publication Catherine Chirouze
Service de Maladies Infectieuses et Tropicales, CHU Besancon, F-25000, France ; UMR-CNRS 6249 Chrono-environnement, Université de Franche-Comté, 25000 Besançon, France
1 shared publication
Latest Publications
- Open Access
- 31 October 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (11)
Shotgun Metagenomics Versus 16S rDNA Sanger Sequencing for the Diagnosis of Blood Culture-Negative Endocarditis: A Draw?
Although valuable for diagnosing blood culture-negative infective endocarditis, 16S rDNA sequencing and metagenomics on valve/vegetation have never been compared using identical DNA extracts. We compared methods on surgical samples from definite, possible, and rejected infective endocarditis involving culture-negative native valves. Positivity rates were similar, with taxonomic resolution being higher for metagenomics.
- 31 October 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (11)
Open AccessShotgun Metagenomics Versus 16S rDNA Sanger Sequencing for the Diagnosis of Blood Culture-Negative Endocarditis: A Draw?
Although valuable for diagnosing blood culture-negative infective endocarditis, 16S rDNA sequencing and metagenomics on valve/vegetation have never been compared using identical DNA extracts. We compared methods on surgical samples from definite, possible, and rejected infective endocarditis involving culture-negative native valves. Positivity rates were similar, with taxonomic resolution being higher for metagenomics.
- 24 October 2023
- Published by Elsevier in Médecine et Maladies Infectieuses Formation
- Vol. 2 (4) , 192-204
Les Orthohantavirus du Nouveau Monde
- 24 October 2023
- Published by Elsevier in Médecine et Maladies Infectieuses Formation
- Vol. 2 (4) , 192-204
Les Orthohantavirus du Nouveau Monde
- 13 August 2022
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 77 (10) , 2701-2705
Infective endocarditis in pregnant women without intravenous drug use: a multicentre retrospective case series
To describe the clinical features and outcomes of infective endocarditis (IE) in pregnant women who do not inject drugs. A multinational retrospective study was performed at 14 hospitals. All definite IE episodes between January 2000 and April 2021 were included. The main outcomes were maternal mortality and pregnancy-related complications. Twenty-five episodes of IE were included. Median age at IE diagnosis was 33.2 years (IQR 28.3–36.6) and median gestational age was 30 weeks (IQR 16–32). Thirteen (52%) patients had no previously known heart disease. Sixteen (64%) were native IE, 7 (28%) prosthetic and 2 (8%) cardiac implantable electronic device IE. The most common aetiologies were streptococci (n = 10, 40%), staphylococci (n = 5, 20%), HACEK group (n = 3, 12%) and Enterococcus faecalis (n = 3, 12%). Twenty (80%) patients presented at least one IE complication; the most common were heart failure (n = 13, 52%) and symptomatic embolism other than stroke (n = 4, 16%). Twenty-one (84%) patients had surgery indication and surgery was performed when indicated in 19 (90%). There was one maternal death and 16 (64%) patients presented pregnancy-related complications (11 patients ≥1 complication): 3 pregnancy losses, 9 urgent Caesarean sections, 2 emergency Caesarean sections, 1 fetal death, and 11 preterm births. Two patients presented a relapse during a median follow-up of 3.1 years (IQR 0.6–7.4). Strict medical surveillance of pregnant women with IE is required and must involve a multidisciplinary team including obstetricians and neonatologists. Furthermore, the potential risk of IE during pregnancy should never be underestimated in women with previously known underlying heart disease.
- 13 August 2022
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 77 (10) , 2701-2705
Infective endocarditis in pregnant women without intravenous drug use: a multicentre retrospective case series
To describe the clinical features and outcomes of infective endocarditis (IE) in pregnant women who do not inject drugs. A multinational retrospective study was performed at 14 hospitals. All definite IE episodes between January 2000 and April 2021 were included. The main outcomes were maternal mortality and pregnancy-related complications. Twenty-five episodes of IE were included. Median age at IE diagnosis was 33.2 years (IQR 28.3–36.6) and median gestational age was 30 weeks (IQR 16–32). Thirteen (52%) patients had no previously known heart disease. Sixteen (64%) were native IE, 7 (28%) prosthetic and 2 (8%) cardiac implantable electronic device IE. The most common aetiologies were streptococci (n = 10, 40%), staphylococci (n = 5, 20%), HACEK group (n = 3, 12%) and Enterococcus faecalis (n = 3, 12%). Twenty (80%) patients presented at least one IE complication; the most common were heart failure (n = 13, 52%) and symptomatic embolism other than stroke (n = 4, 16%). Twenty-one (84%) patients had surgery indication and surgery was performed when indicated in 19 (90%). There was one maternal death and 16 (64%) patients presented pregnancy-related complications (11 patients ≥1 complication): 3 pregnancy losses, 9 urgent Caesarean sections, 2 emergency Caesarean sections, 1 fetal death, and 11 preterm births. Two patients presented a relapse during a median follow-up of 3.1 years (IQR 0.6–7.4). Strict medical surveillance of pregnant women with IE is required and must involve a multidisciplinary team including obstetricians and neonatologists. Furthermore, the potential risk of IE during pregnancy should never be underestimated in women with previously known underlying heart disease.
- 1 June 2019
- Published by Elsevier in Medecine Et Maladies Infectieuses
- Vol. 49 (4) , S59-S60
Pertinence de l’usage de la daptomycine dans un centre hospitalier universitaire : étude rétrospective monocentrique
- 1 June 2019
- Published by Elsevier in Medecine Et Maladies Infectieuses
- Vol. 49 (4) , S59-S60
Pertinence de l’usage de la daptomycine dans un centre hospitalier universitaire : étude rétrospective monocentrique
- 1 June 2016
- Published by Elsevier in Medecine Et Maladies Infectieuses
- Vol. 46 (4) , 125
VIH-23 - Bithérapies d’antirétroviraux chez des patients infectés par le VIH : efficacité et tolérance
- 1 June 2016
- Published by Elsevier in Medecine Et Maladies Infectieuses
- Vol. 46 (4) , 125
VIH-23 - Bithérapies d’antirétroviraux chez des patients infectés par le VIH : efficacité et tolérance